Loading viewer...
investor_presentation
Format: PDF investor_presentation
9M 2022 Results Swiss Re investor and analyst presentation Zurich, 28 October 2022
Swiss Re investor and analyst presentation
Zurich, 28 October 20229M 2022 Results
Reinsurance106.1%9M 2022
1Net premiums earned and fee income
3At constant fxrates
4Assuming an average large nat cat loss burden and excluding prior -year reserve developmentNet income
(+5.0%3)1 19.5%Q3 2022
Solutions93.1% 92.9% Combined ratioNormalised4
Reinsurance221m 219m Net income (USD)
Group-2.1% -13.2% Return on equity2
2Swiss Re GroupThird quarter performance heavily impacted by elevated P&C Reinsurance loss activity,
while L&H Reinsurance and Corporate Solutions delivered strong results9M 2022 Results
9M 18 9M 19 9M 20 9M 21 9M 22
3Combined ratioCorporate Solutions P&C Reinsurance
•9M 2022 reported combined ratio impacted by large nat cat losses
(7.4%pts above expectations), mainly driven by Hurricane Ian
•9M 2022 reported and normalised1combined ratios additionally
affected in Q3 2022 by higher small -to mid -sized claims, mostly
driven by economic inflation
•Unlikely to reach <94% normalised1combined ratio target for 202295%
100%110%120%125%130%
9M 19 9M 18 9M 20 9M 21 9M 22
•9M 2022 reported combined ratio slightly higher compared to 9M
2021, primarily driven by less favourable prior -year development
•elipsLife sale completed with effect from 1 July 2022. Excluding
elipsLife 9M 2022 pro forma2combined ratio of 91.6%
•Well on track to achieve <95% reported combined ratio target for
2022Reported Normalised1
93.1%ReportedCorporate Solutions well on track to achieve its 2022 combined ratio target, while P&C
Re’s result impacted by elevated nat cat losses and higher small -to mid -sized claims
Preview truncated — download the full document for the complete content.
conference
26 Pages
investor_presentation
29 Pages
INVO Bioscience
Varian Medical Systems Investor Presentation — January 2018
investor_presentationinvestor_presentation
21 Pages
Varian Medical Systems, Inc.